Call for Interest in Translational Cancer Research

28 April 2022 3minutes

Please note that the call is now closed

A call was launched to identify collaborative translational research projects focused on the domains below. The selected proposals will be integrated into the next phase of the final application to the sponsors. Integrative proposals covering more than one thematic involving clinicians and scientists was appreciated.

Prevention & Care

High resolution epidemiology data impacting on life style, quality of care and quality of life. This thematic will focus on improving prevention, early cancer detection, quality of treatment and quality of life. It will make use of high resolution data from the cancer registry and connect with secondary data sources (e.g. socioeconomic databases).

Digital Technologies and Patient Reported Outcomes

Patient-centric cancer care and research. The use of digital technologies will be investigated for real-life monitoring of cancer patients: to promote the inclusion of Patient-Reported Outcomes in routine cancer care and to identify digital biomarkers for personalized cancer care.

Multi-omics Patient Profiling

Precision oncology to improve cancer diagnostic and treatment. Comprehensive molecular profiling of patient tumors and the tumor ecosystem. This includes e.g. genomics, epigenetic profiling, transcriptomics, immunophenotyping as well as development of bioinformatic pipelines for integrative data analysis.

Complex Patient-based Models

Improving pre-clinical model systems for clinically relevant output. Application of complex patient-based pre-clinical models incorporating components of the tumor microenvironment and immune system, (e.g patient-derived organoids, iPSC, organ-on-a-chip, microfluidics, in vivo humanized models), leading to clinically relevant drug/target validation and treatment advice (e.g. Personalized Functional Profiling, PFP).

Innovative Immunotherapies

Focus on experimental cellular immunotherapies.

Cell-based immunotherapies represent a promising breakthrough for cancer treatment and an active research focus to benefit from the full capacity of the immune system. Efforts for off-the-shelf solutions or personalized approaches of cellular adoptive immunotherapies could be envisaged to become available to cancer patients in Luxembourg.

Data Integration & Analysis

Making sense of large scale clinical/biomedical data. Various omics-data, clinical and imaging data will be generated or collected throughout the program, requiring high level bioinformatics pipelines for integrative analysis and development of AI-driven applications to improve diagnostics, treatment-decisions and patient care.

Call Guidelines

 The call is closed now

Review and ranking will be done by the SAB of the NCTCR INITIATE project. The evaluation will be based on scientific merit, translational impact and strategic fit into the program. The final assessment for integration into the proposal is subject to the NCTCR steering committee.

Feedback to applicants will be communicated before the end of September 2022.

Contact : Simone Niclou

Scientific Advisory Board

Stephan Fröhling, Director NCT Heidelberg, Germany

Gilles Favre, Director CRCT Toulouse (IUCT-Oncopole), France

Otto Visser, Director Netherlands Comprehensive Cancer Organization (IKNL), Netherlands

Latest News